About this Webinar
Join the Pharma Investigative News team, Reynald Castañeda and Manasi Vaidya, for a deep dive into the upcoming virtual American Society of Clinical Oncology (ASCO) conference, the largest annual meeting for stakeholders and KOLs involved in cancer drug development.
The webinar will last approximately 45 minutes and will:
• Discuss the most exciting oncology news that is to be presented at ASCO
• Examine what the announcements mean for the treatment landscape
• Understand the KOL perspective based on the investigative news team’s reporting
• Probe what lies in the future for oncology therapies
Speakers
Reynald Castañeda
Reynald joined GlobalData’s Pharma Investigative News team (formerly BioPharm Insight) as a journalist in September 2015. Reynald writes in-depth news stories and scoops on drug development in a wide variety of beats, including cardiology, dermatology, liver diseases, oncology and, most recently, COVID-19 vaccines. Previously, he was a journalist for primary care newspaper New Zealand Doctor. He has a BSc in Biological Sciences from the University of Auckland and a postgraduate diploma in journalism from AUT University.
Manasi Vaidya
Manasi Vaidya joined as a reporter in New York in February 2015 and has covered the drug development space across several therapeutic areas, building an expertise in writing about oncology. While focusing on analysis pieces about ongoing clinical trials, her coverage has also branched out to regulatory issues, pricing and reimbursement and patent litigation. She previously covered the Asian biotechnology industry for BioSpectrum, a monthly magazine in India. She has a master’s degree in Science, Health and Environmental Reporting from New York University. Her work has appeared in Nature Medicine, Nautilus and Technology Review India.
Past Webinars
View more past webinarsUpcoming Webinars
View more upcoming webinarsSearch companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer


